Treatments

The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.

You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.

Become a Partner.

Country Product Indication Sponsor Date
RII retinamide Myelodysplastic syndromes Sparta Pharmaceuticals, Inc.;111 Rock Road;Horsham, Pennsylvania, 19044 May 6, 1993
Monolaurin Congenital primary ichthyosis Glaxo Wellcome Inc.;5 Moore Drive, PO Box 13398;Research Triangle Park, North Carolina, 27709 April 29, 1993
Factor XIII, recombinant Congenital factor XIII deficiency Zymogenetics, Inc.;4225 Roosevelt Way;Seattle, Washington, 98105 April 22, 1993
Apomorphine HCl The on-off fluctuations associated with late-stage Parkinson's disease US WorldMeds, LLC;4010 Dupont Circle, Suite L-07;Louisville, Kentucky, 40207 April 22, 1993
Protein C concentrate For use in the prevention and treatment of purpura fulminans in meningococcemia Immuno Clinical Research Corp.;750 Lexington Avenue, 19th Floor;New York, New York, 10022 April 22, 1993
Cladribine Non-Hodgkin's lymphoma Janssen Research & Development, LLC;920 US Highway 202;Raritan, New Jersey, 08869 April 19, 1993
Aminosalicylate sodium Crohn's disease Syncom Pharmaceuticals, Inc.;66 Hanover Road;Florham Park, New Jersey, 07932 April 6, 1993
Riluzole Amyotrophic lateral sclerosis Rhone-Poulenc Rorer Pharmaceuticals, Inc.;500 Arcola Road, P.O. Box 1200;Collegeville, Pennsylvania, 19426 March 16, 1993
Atovaquone Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis GlaxoSmithKline, Inc.;5 Moore Drive, PO Box 13398;Research Triangle Park, North Carolina, 27709 March 16, 1993
Atovaquone Treatment and suppression of Toxoplasma gondii encephalitis GlaxoSmithKline, Inc.;5 Moore Drive, PO Box 13398;Research Triangle Park, North Carolina, 27709 March 16, 1993
Modafinil Excessive daytime sleepiness in narcolepsy Cephalon, Inc.;145 Brandywine Parkway;West Chester, Pennsylvania, 19380 March 15, 1993
Daclizumab Prevention of acute renal allograft rejection Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 March 5, 1993
Humanized anti-tac Prevention of acute graft-vs-host disease following bone marrow transplantation Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 March 5, 1993
Immune globulin intravenous, human Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus Bayer Corporation;Pharmaceutical Division, Biological Products, 400 Morgan Lane;New Haven, Connecticut, 06516 February 18, 1993
Somatropin Cachexia associated with AIDS Bio-Technology General Corp.;70 Wood Avenue, South;Iselin, New Jersey, 08830 February 12, 1993
Tretinoin Acute and chronic leukemia Antigenics, Inc.;3 Forbes Road;Lexington, Massachusetts, 02421 January 14, 1993
Interferon beta (recombinant human) Primary brain tumors Biogen Idec, Inc.;14 Cambridge Center;Cambridge, Massachusetts, 02142 January 13, 1993
Thalidomide The clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria Celgene Corporation;7 Powder Horn Dr.;Warren January 12, 1993
Colfosceril palmitate, cetyl alcohol, tyloxapol Adult respiratory distress syndrome GlaxoSmithKline;5 Moore Drive, P.O. Box 13398;Research Triangle Park, North Carolina, 27709 January 11, 1993
Cystic fibrosis transmembrane conductance regulator gene Cystic fibrosis Genetic Therapy, Inc.;938 Clopper Road;Gaithersburg, Maryland, 20878 January 8, 1993
Monoclonal antibody for immunization against lupus nephritis Lupus nephritis VivoRx Autoimmune, Inc.;2825 Santa Monica Blvd., Suite 200;Santa Monica, California, 90404 January 7, 1993
Tumor necrosis factor-binding protein 1 Symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3 EMD Serono, Inc.;One Technology Place;Roackland, Massachusetts, 02370 January 6, 1993
Tumor necrosis factor-binding protein II Symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3 EMD Serono, Inc.;One Technology Place;Roackland, Massachusetts, 02370 January 6, 1993
Transforming growth factor-beta 2 Full thickness macular holes Celtrix Pharmaceuticals, Inc.;3055 Patrick Henry Drive;Santa Clara, California, 95054 December 18, 1992
Isobutyramide Beta-thalassemia Perrine, Susan P., M.D.;Boston University, Cancer Research Center;Boston, Massachusetts, 02118 December 18, 1992